Overview and Scope
Nivolumab refers to an immunoglobulin G4 (IgG4) completely human antibody that targets programmed cell death protein 1 (PD1) and is licensed at a dose of 3 mg/kg for metastatic or unresectable melanoma, metastatic non-small cell lung cancer following platinum-based chemotherapy and metastatic renal cell carcinoma in the second-line context. It is a targeted therapy medication used to manage and treat a variety of cancers. It functions by boosting the immune system.
Sizing and Forecast
The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.
The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report
The nivolumab market covered in this report is segmented –
1) By Type: Injection 4mL; Injection 10mL
2) By Route Of Administration: Intravenous; Other Routes Of Administration
3) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
4) By End-User: Clinic; Hospital; Other End-Users
North America was the largest region in the nivolumab market in 2023. The regions covered in nivolumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=13012&type=smp
Major Driver Impacting Market Growth
The rising prevalence of cancer is expected to propel the growth of the nivolumab market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries and either spread to other organs or invade neighboring body parts. Nivolumab is used to manage and treat several types of cancer by keeping cancer cells from suppressing the immune system and allowing the immune system to attack and kill the cancer cells. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase compared to more than 1.8 million new cancer cases diagnosed in 2020. Therefore, the rising prevalence of cancer is driving the growth of the nivolumab market.
Key Industry Players
Major players in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.
The nivolumab market report table of contents includes:
1. Executive Summary
2. Nivolumab Market Characteristics
3. Nivolumab Market Trends And Strategies
4. Nivolumab Market – Macro Economic Scenario
…
32. Global Nivolumab Market Competitive Benchmarking
33. Global Nivolumab Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Nivolumab Market
35. Nivolumab Market Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global arket Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Ski refers to a piece of wood or a stick with slats…
Overview and Scope Single-cell genome sequencing is a potent method for detecting genomic changes like…
Overview and Scope A seismic survey refers to a type of geophysical survey that attempts…
Overview and Scope A single-board computer (SBC) is a complete computing device that is built…
Overview and Scope Running shoes refer to a form of footwear that is particularly intended…
Overview and Scope Lithium-ion battery binders refer to the materials designed to hold together the…